Current Situations Of Kidney Cancer And Its Study

Current Situations Of Kidney Cancer And Its Study

By:


Current situations of kidney cancer and its study

There were an estimated 58,000 new patients and 13,000 deaths of kidney cancer. For localized kidney cancer, nephrectomy is the mainstay of treatment; however, approximately 30% of patients with kidney cancer will develop recurrence (ie, stage IV or metastatic disease). Additionally, as many as one-third of all patients present with metastatic disease at initial diagnosis. About 90% of kidney cancers are renal cell carcinomas (RCC), and up to 80% of these are of clear-cell histology. In spite of limited clinical efficacy and significant toxicity, cytokine therapies (interferon-? [IFN-?] and interleukin-2 [IL-2]) were the standard of care in the pre-targeted treatment era. However, understanding of the pathogenesis of sporadic (non-inherited) clear cell RCC has led to advances in treatment for advanced RCC and the advent of the targeted therapy era. Specifically, it is now understood that dysregulation of the von Hippel-Lindau (VHL) tumor preventer gene results in intracellular accumulation of the hypoxia-inducible factor (HIF), which leads to secretion of factors under its control: vascular endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and other factors. Strives to target HIF-related pathways have shown successful thus far in treatment of advanced RCC, with the bulk centered around prevention of the VEGF axis ("downstream" of HIF) and mammalian target of rapamycin axis ("upstream" of HIF).[1]

Advanced treatment options

Therapeutic selectivity for advanced RCC has now dramatically elevated, with six new treatments. Three multi-targeted tyrosine kinase inhibitors of the VEGFR and PDGFR have been approved: sorafenib (Nexavar), sunitinib (Sutent), and pazopanib (Votrient). Two drugs that prevent mTOR have been approved: temsirolimus (Torisel) and everolimus (Afinitor). Finally, a humanized monoclonal antibody against VEGF, bevacizumab (Avastin), was agreed in combination with interferon-?. While there are now multiple selections from which patients with mRCC and their doctors may choose, there may be more than one reasonable choice in a particular setting and little evidence to guide amongst them. In these situations, when head-to-head comparisons of efficacy have not been performed, clinical decisions may be made based on other factors, like toxicity profiles and route of administration, as well as patient comorbidities, and financial considerations. E.g., sunitinib has been the standard of care for treatment-nave patients with good-intermediate risk clear cell RCC. Recently, bevacizumab + IFN-? and pazopanib have provided additional options in this setting. We believe that more options will appears in the future. We expect them to bring brilliant tomorrow for patients with kidney cancer.

About the Author:
We has established long-term and stable relationships with more than 10,000 customers from pharmaceutical and biotech companies, universities and research institutions. We have high quality inhibitors like Sunitinib, Temsirolimus, Vorinostat & more. We have headquarter



Article Originally Published On: http://www.articlesnatch.com


Tags:

|

Loading...
Related....
Videos...

Recent Arts-and-Entertainment Articles

Comments

Still can't find what you are looking for? Search for it!

Loading

Site Navigation:

Copyright 2005-2011 ArticleSnatch, LLC - All Rights Reserved.
Privacy Policy | Terms of Service.